| Anthem Blue Cross | Defined Composition Cellular Immunotherapy for Select Leukemias or Myelodysplastic Syndrome | 2026-07-15 |
| BCBS Illinois Medical Policies | Biomarker Testing in Risk Assessment and Management of | 2026-07-15 |
| BCBS Illinois Medical Policies | Obinutuzumab | 2026-07-15 |
| BCBS Oklahoma Medical Policies | Biomarker Testing in Risk Assessment and Management of | 2026-07-15 |
| BCBS Oklahoma Medical Policies | Obinutuzumab | 2026-07-15 |
| BCBS Texas Medical Policies | Biomarker Testing in Risk Assessment and Management of | 2026-07-15 |
| BCBS Texas Medical Policies | Obinutuzumab | 2026-07-15 |
| BCBS New Mexico Medical Policies | Biomarker Testing in Risk Assessment and Management of | 2026-07-15 |
| BCBS New Mexico Medical Policies | Obinutuzumab | 2026-07-15 |
| Medicare Wellpoint Federal | Billing and Coding: Botulinum Toxin Injections (59707) | 2026-07-15 |